The Role of Anticholinergic Therapy in Moderate to Severe Asthma

Slides:

Advertisements

Similar presentations

Global Initiative for Asthma (GINA) What’s new in GINA 2015?

Advertisements

1 British Guideline on the Management of Asthma BTS/SIGN British Guideline on the Management of Asthma, May 2008 Introduction Diagnosis Non-pharmacological.

Tiotropium Bromide Step-Up Therapy for Adults with Uncontrolled Asthma Stephen P. Peters, M.D., Ph.D., Susan J. Kunselman, M.A., Nikolina Icitovic, M.A.S.,

LSU Journal Club Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD WISDOM study H. Magnussen MD, et al. Nisha Loganantharaj, PGY1 April 21,

내과 R2 이지훈 N Engl J Med Sep 8.

Attaran D, Mashhad university of medical sciences.

Global Initiative for Asthma (GINA) What’s new in GINA 2015?

The Nurse View.

Practical Recommendations for COPD:

An Interprofessional Approach to Optimizing Patient Care in Allergy

Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.

How the Latest Data in MDD Can Guide Treatment Decisions:

RESISTANT HYPERTENSION OR POOR PATIENT ADHERENCE? TIPS TO GAIN CONTROL

Optimizing Outcomes in Short Bowel Syndrome With IF

Know Your ABCs: Antiplatelet Therapy, Benefits/Bleeding, and Cardiac Surgery State of the Art: The Role of Antiplatelet Therapy in the Cardiac Surgical.

Optimizing Use of Biological Agents in Ulcerative Colitis

A CASE CHALLENGE IN HFrEF:

Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?

Clinical Review.

Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.

Seasonal Allergic Rhinitis

Managing Hereditary Angioedema

Optimizing the Treatment of Recurrent/Metastatic SCCHN

Optimizing Outcomes in the Management of GIST

Statin Selection in Special Patient Populations: A Case Challenge

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

Program Goals Introduction Case 1: A 44-Year-Old Woman.

Advances in Severe Asthma Perspectives From San Antonio 2015

Translating Atopic Dermatitis

Treatment Options to Consider

VTE Treatment Conventional Approach

Patient Case: KC. Optimizing Treatment of Mild to Moderate Ulcerative Colitis: A Case-Based Perspective.

PCSK9 Inhibitors and Cardiovascular Outcomes

Targeting Osteoporosis Therapies to Patients at Highest Risk for Fracture.

A Better Solution For Cancer Patients With VTE?

Atopic Dermatitis. Introduction to a Clinical Course On New Developments In Atopic Dermatitis.

Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.

The Evolving Treatment Landscape in Atopic Dermatitis

The Road to Quality Improvement in HER2-Positive Breast Cancer

Understanding and Addressing the Needs of Patients With AD

A Time for Change for Managing Patients With VTE Who Have Cancer

Implications of Emerging Treatments for Beta-Thalassemia

A) Peak forced expiratory volume in 1 s within 3 h post-dosing (peak FEV10–3h) response following once-daily tiotropium Respimat add-on to medium-dose.

Managing Pulmonary Embolism Posthospital Discharge

A Nursing Perspective on Improving Outcomes for Patients With Hemophilia.

Global Initiative for Asthma (GINA) What’s new in GINA 2015?

Etiology and Incidence Pathophysiology Hemophilia is due to a defect in thrombin generation on the platelet surface.

Diagnosis, Evaluation, and Therapy for Severe Refractory Eosinophilic Asthma.

Challenges in LA SCCHN.

Introduction. Emerging Treatments for Thrombocytopenia in Adults With CLD Requiring Elective Invasive Procedures.

Inhaled Antibiotics for Patients With CF in the Era of CFTR Modulators

A Multidisciplinary Perspective on the Management of Hypoparathyroidism.

Practical Strategies for Getting Patients With Diabetes to Lipid Goal

Optimizing Outcomes for Patients With Systemic Lupus Erythematosus: Key Considerations.

Optimizing Front-Line Endocrine Therapy in Metastatic Breast Cancer

AMD Therapy: Where Are We Now and Where Are We Going?

VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.

Clinical Comparisons in CTEPH

Practical Recommendations for COPD:

Where Does Anticholinergic Therapy Fit in Moderate to Severe Asthma?

The Asthma Treatment Gap

PCSK9 Inhibitors and Real-World Evidence

Exploring the Role of Biologics in Reducing Oral Corticosteroid Use in Severe Asthma.

Foundations of Asthma.

Navigating the Journey

Presentation transcript:

The Role of Anticholinergic Therapy in Moderate to Severe Asthma

Introduction

Definitions of Severe and Uncontrolled Asthma

Asthma in The World

Uncontrolled Severe Asthma Is a Significant Problem

Guideline Goals for Successful Asthma Management

GOAL: 22-38% of Asthma Patients Remained Uncontrolled Despite Optimal ICS/LABA-Treatment

Uncontrolled Asthma Checklist

What Are the Possible Reasons for Poor Disease Control?

Asthma Control in the INSPIRE Study

Asthma in Children 5 Years and Younger

Asthma Treatment in Adults and Adolescents

Stepwise Approach to Long-Term Management of Asthma in Children 5 Years and Younger

Asthma Treatment in Adults and Adolescents

The Cholinergic System Contributes to Bronchoconstriction in Asthma

The TALC Study Trial Design

Primary and Secondary Outcomes

Tiotropium in Asthma Poorly Controlled With ICS/LABA

Tiotropium in Asthma Poorly Controlled With ICS/LABA (cont)

Tiotropium or Salmeterol as Add-On Therapy to ICS for Moderate Symptomatic Asthma

Tiotropium or Salmeterol as Add-On Therapy to ICS for Moderate Symptomatic Asthma (cont)

Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose ICS

Tiotropium in Asthma <18 Years

Tiotropium in Asthma <18 Years (cont)

Tiotropium Efficacy

Tiotropium in Asthma

Tiotropium Safety (Moderate Asthma)

Tiotropium Safety (Severe)

Safety of Add-On LAMA Therapy

Treatment Options in Step 5

Uncontrolled Asthma Checklist

Conclusion

Abbreviations

Abbreviations (cont)